Polyrizon Ltd., a biotechnology company focused on developing intranasal products, has announced promising preclinical results for its PL-14 Allergy Blocker as part of its proprietary Capture & Contain platform. Conducted in collaboration with the University of Parma, the study assessed the product's performance in delivering targeted deposition to the nasal vestibule, a key site for allergen contact. The results, presented using a validated silicone-based human nasal cast, showed over 60% deposition in the nasal vestibule. This targeted delivery supports PL-14's potential as a barrier-forming treatment for allergic rhinitis. Polyrizon plans to continue preclinical validation and move toward clinical trials to further develop its C&C platform.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。